WGS
GeneDx Holdings Corp.
$63.61
-6.61
(-9.41%)
Mkt Cap
1.90B
Volume
644,169
52W Range
32.21-170.87
Sector
Healthcare
Beta
1.97
EPS (TTM)
-3.64 USD
P/E Ratio
-178.16
Revenue (TTM)
454.43M USD
Rev Growth (5Y)
+19.0%
EPS Growth (5Y)
N/A
Company Description
GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. It also develops an AI-based platform for next generation sequencing analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing. GeneDx Holdings Corp. was founded in 2000 and is headquartered in Stamford, Connecticut.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 427.54M | 305.45M | 202.57M | 234.69M | 212.19M | 179.32M | 196.17M |
| Net Income | (21.02M) | (52.29M) | (175.77M) | (548.98M) | (245.39M) | (241.34M) | (29.70M) |
| EPS | -0.73 | -1.94 | -7.23 | -53.63 | -74.93 | -33.16 | -4.26 |
| Free Cash Flow | 14.26M | (33.99M) | (185.86M) | (333.48M) | (211.22M) | (125.10M) | (34.18M) |
| FCF / Share | 0.53 | -1.26 | -7.64 | -32.58 | -64.49 | -22.23 | -6.08 |
| Operating CF | 33.28M | (28.50M) | (180.15M) | (319.15M) | (190.43M) | (93.13M) | (18.73M) |
| Total Assets | 570.19M | 419.38M | 418.76M | 545.26M | 554.09M | 251.64M | N/A |
| Total Debt | 151.95M | 116.17M | 119.77M | 77.13M | 32.85M | 43.26M | N/A |
| Cash & Equiv | 105.00M | 85.21M | 99.68M | 137.40M | 400.57M | 108.13M | N/A |
| Book Value | 308.18M | 245.25M | 228.02M | 253.71M | 388.10M | 4.39M | N/A |
| Return on Equity | -0.07 | -0.21 | -0.77 | -2.16 | -0.63 | -55.00 | N/A |
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 114.44M | 102.25M | 120.99M | 116.74M | 102.69M | 87.11M | 95.64M | 76.87M | 70.51M | 62.42M | 57.42M | 53.30M |
| Net Income | (17.74M) | (63.32M) | (17.67M) | (7.63M) | 10.81M | (6.53M) | 5.44M | (8.31M) | (29.17M) | (20.24M) | (25.77M) | (42.29M) |
| EPS | -0.60 | -2.16 | -0.61 | -0.27 | 0.38 | -0.23 | 0.20 | -0.31 | -1.10 | -0.78 | -0.99 | -1.64 |
| Free Cash Flow | (39.09M) | (38.86M) | (7.44M) | 9.60M | 8.05M | 4.05M | (6.23M) | (5.04M) | (5.86M) | (16.86M) | (32.23M) | (41.09M) |
| FCF / Share | -1.32 | -1.32 | -0.28 | 0.33 | 0.28 | 0.14 | -0.23 | -0.19 | -0.22 | -0.65 | -1.24 | -1.59 |
| Operating CF | (28.98M) | (32.41M) | (3.09M) | 15.77M | 10.42M | 10.18M | (3.18M) | (4.39M) | (4.50M) | (16.41M) | (29.86M) | (40.98M) |
| Total Assets | 481.49M | 506.30M | 570.19M | 493.90M | 463.86M | 446.43M | 419.38M | 408.84M | 389.10M | 394.53M | 418.76M | 417.29M |
| Total Debt | 167.40M | 168.19M | 151.95M | 113.16M | 114.39M | 114.84M | 116.17M | 116.10M | 116.96M | 123.21M | 119.77M | 73.62M |
| Cash & Equiv | 60.32M | 93.92M | 105.00M | 95.97M | 74.12M | 99.70M | 85.21M | 57.89M | 56.08M | 83.67M | 99.68M | 87.39M |
| Book Value | 244.22M | 254.12M | 308.18M | 292.26M | 277.13M | 257.40M | 245.25M | 204.50M | 194.04M | 207.22M | 228.02M | 254.26M |
| Return on Equity | -0.07 | -0.25 | -0.06 | -0.03 | 0.04 | -0.03 | 0.02 | -0.04 | -0.15 | -0.10 | -0.11 | -0.17 |
WGS News
Comparing GeneDx (NASDAQ:WGS) & Brookdale Senior Living (NYSE:BKD)
GeneDx Presents New Evidence Advancing Genomic Newborn Screening at ICoNS 2026
GeneDx Presents New Evidence Advancing Genomic Newborn Screening at ICoNS 2026
GeneDx Holdings Corp (WGS) Shares Surge 4.3% -- What GF Score of 67 Tells Investors
GeneDx Introduces Easy Order at AAP 2026 to Simplify Genomic Testing in Everyday Pediatric Care
Kevin Feeley Sells 3,728 Shares of GeneDx (NASDAQ:WGS) Stock
Tempus Launches Effort to Build the Largest Multimodal Whole-Genome Dataset to Advance AI-Driven Healthcare Innovation
GeneDx and Beren Therapeutics Launch NPC GenomeComplete to Improve Diagnosis of Niemann-Pick Disease Type C
3 Promising Genomics Stocks in the Spotlight in 2026
GeneDx CEO Katherine Stueland Recognized as a 2026 Fierce 50 Honoree